Beryl Drugs FAQs
As of 08-2026, the promoter shareholding in Beryl Drugs stands at 27.82% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Beryl Drugs is 0% and 0% respectively.
The retail shareholding of the Beryl Drugs is 72.18%.
Changes in shareholding patterns of Beryl Drugs can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Beryl Drugs are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
